JAK Inhibitors for Axial Spondyloarthritis: What does the Future Hold?
Nurullah Akkoç, Muhammad Asim Khan
Topics & Concepts
MedicineTofacitinibClinical endpointPlaceboInternal medicineAdverse effectAnkylosing spondylitisRandomized controlled trialJanus kinase inhibitorAxial spondyloarthritisSafety profileRheumatologyRheumatoid arthritisAlternative medicineSacroiliitisPathologySpondyloarthritis Studies and TreatmentsRheumatoid Arthritis Research and TherapiesCytokine Signaling Pathways and Interactions